Oxford’s COVID-19 Vaccine Prevents Virus Transmission: Study


Oxford’s COVID-19 Vaccine Prevents Virus Transmission: Study


Oxford-AstraZeneca’s vaccine significantly reduces virus transmission and is highly protective after a single dose. This emerges from a study by the University of Oxford, which the British government described on Wednesday as a confirmation of its vaccination strategy.

“It shows the world that the Oxford Jab works, it works well,” Health Secretary Matt Hancock told BBC Radio, hailing the study’s results as “good news.”

“It slows down the transmission by around two-thirds, so it categorically supports the strategy we’re pursuing,” said Hancock.

The results of the study have been discussed in many debates about the effectiveness of the AstraZeneca sting in the elderly.

Although the European Medicines Agency recommended it for adults of all ages last week, several countries have advised against giving the AstraZeneca push to elderly people.

Germany has already said it won’t advise people over 65 to get it.

The Italian Medicines Agency approved the vaccine for all adults on Saturday but recommended alternatives for people over 55.

And French President Emmanuel Macron said last week that the vaccine against Oxford-AstraZeneca was “virtually ineffective” for those over 65.

The UK has been on lockdown since December with schools closed and no final end date, although a review of the situation is expected in mid-February.

The country had 3.8 million cases and 108,013 deaths.

The Oxford study, awaiting peer review, found that those who had been vaccinated with a single dose of the vaccine were 67 percent less likely to test positive with a PCR test, “suggesting the potential for significant Decrease in transmission indicates “.


Dosing schedule

It also supported the UK’s strategy of giving high risk groups as many first doses of the vaccine as possible and allowing an interval of 12 weeks before the second dose, which has been criticized by some experts.

The other vaccine, which has already been launched in the UK, Pfizer-BioNTech, should be given more frequently.

“We are confident that the 12-week dosing schedule is the right one for both vaccines we use in the UK,” Hancock said on Wednesday.

The researchers found that a single dose was 76 percent effective against virus symptoms after 22 days and up to 90 days, while it did not prevent asymptomatic disease.

It was more effective to wait 90 days than to give the second dose. The researchers noted that “current policy continues to be supported”.

The survey had 17,177 participants in the UK, Brazil and South Africa. The data refer to the period up to December 7, 2020. None of the people examined were hospitalized.

Invented by scientists at Oxford University, the vaccine is developed and manufactured by AstraZeneca.

The vaccine is cheap to manufacture and is sold at cost. It can also be stored at refrigerator temperature, while Pfizer vaccine must be stored extremely cold.

(This story was not edited by GossipMantri staff and is automatically generated from a syndicated feed.)


Please enter your comment!
Please enter your name here